8-KMaterial AgreementsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Dec 21, 2004)

Filed December 21, 2004For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) announced a significant development in its HIV treatment portfolio through an 8-K filing on December 20, 2004. The company, along with Bristol-Myers Squibb Company, entered into a material definitive agreement to form a jointly owned limited liability company. This new entity will focus on the development and commercialization of a fixed-dose combination therapy in the United States. The collaboration centers on combining Gilead's Truvada™ (emtricitabine and tenofovir disoproxil fumarate) with Bristol-Myers Squibb's Sustiva® (efavirenz). This strategic partnership aims to leverage the strengths of both companies to bring a more convenient and potentially more effective treatment option to patients battling HIV. Investors should view this as a positive step towards expanding Gilead's market presence and product offerings in the critical HIV therapeutic area.

Key Highlights

  • 1Gilead Sciences (GILD) has entered into a material definitive agreement to form a joint venture with Bristol-Myers Squibb Company.
  • 2The joint venture will focus on the development and commercialization of a fixed-dose combination of HIV medicines in the United States.
  • 3The collaboration includes Gilead's Truvada™ (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb's Sustiva® (efavirenz).
  • 4A new, jointly owned limited liability company has been established to facilitate this collaboration.
  • 5The agreement is designed to accelerate the delivery of a combination HIV therapy to patients.
  • 6This partnership signifies a strategic move to strengthen Gilead's position in the HIV market.

Frequently Asked Questions

The main purpose of the agreement is to jointly develop and commercialize a fixed-dose combination of Gilead's Truvada™ and Bristol-Myers Squibb's Sustiva® for the treatment of HIV in the United States. This involves forming a new, jointly owned limited liability company to manage these efforts.

The collaboration involves Gilead's Truvada™ (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb's Sustiva® (efavirenz).

This collaboration allows Gilead to leverage Bristol-Myers Squibb's expertise and market presence to accelerate the commercialization of a key fixed-dose combination therapy. It aims to provide a more convenient treatment option for HIV patients and potentially expand Gilead's market share in the HIV therapeutic area.

The collaboration agreement was entered into on December 17, 2004, and was reported by Gilead Sciences in an 8-K filing on December 20, 2004.